Research and Development

We are advancing alicaforsen for the treatment of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis. In addition, we are advancing three renzapride clinical programmes for the treatment of GI dysmotility.

Alicaforsen is a novel antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation.

Renzapride is considered best in class orally bioavailable small molecule with a dual mode of action which can increase gut motility and reduce nausea and vomiting.